Article Text

Download PDFPDF
Meningococcal meningitis presenting postinfant group B meningococcal immunisation
  1. Neda So1,2,
  2. Rani Pal3,
  3. Matthew D Snape1,3,4
  1. 1 Department of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, UK
  2. 2 Department of Paediatrics, Monash University, Infection and Immunity, Monash Children’s Hospital, Clayton, Victoria, Australia
  3. 3 Children’s Services, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  4. 4 NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS trust, Oxford, UK
  1. Correspondence to Prof Matthew D Snape, Department of Paediatrics, University of Oxford, Oxford OX3 7LJ, UK; matthew.snape{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We report an infant case of meningococcal group W meningitis presenting within 24 hours of receiving group B meningococcal vaccine (4CMenB), illustrating the dilemma clinicians face in interpreting advice for management of post-immunisation fever and the National Institute for Health and Care Excellence (NICE) fever guidelines, and highlighting the need for sustained vigilance for bacterial infections in infants with post-4CMenB fever.

A 2-month-old girl arrived by ambulance to the local emergency department in April 2017 suffering from right-sided focal limb seizures and fever of 39°C, within 24 hours of receiving her 2-month immunisations (including 4CMenB). The seizure terminated with two doses of intravenous lorazepam and suspected sepsis was treated with immediate intravenous antibiotics.

Investigations revealed a normal cranial CT scan; elevated C-reactive protein (263.5 mg/L (0–5 mg/L)); normal full blood count; normal liver …

View Full Text


  • Contributors NS and RBP wrote the manuscript. MDS and RBP edited the manuscript. RBP was involved in the care of the patient.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MDS conducts clinical trials of vaccines on behalf of the University of Oxford that are funded and/or sponsored by vaccine manufacturers including Glaxosmithkline, Novavax, Pfizer, Medimmune and Sanofi-Pasteur. MDS received no personal financial benefit from these activities. MDS receives salary support from the NIHR Oxford Biomedical Research Centre and is a Jenner Investigator. RBP and NS have no conflicts of interest to declare.

  • Patient consent Parental/guardian consent obtained.

  • Provenance and peer review Not commissioned; internally peer reviewed.